The role of EPID in vivo dosimetry in the risk management of stereotactic lung treatments

[1]  T. Gauer,et al.  Risk management patterns in radiation oncology—results of a national survey within the framework of the Patient Safety in German Radiation Oncology (PaSaGeRO) project , 2022, Strahlentherapie und Onkologie.

[2]  D. Verellen,et al.  Comparing treatment uncertainty for ultra- vs. standard-hypofractionated breast radiation therapy based on in-vivo dosimetry , 2022, Physics and imaging in radiation oncology.

[3]  M. Esposito,et al.  A Validation Method for EPID In Vivo Dosimetry Algorithms , 2021, Applied Sciences.

[4]  M. Esposito,et al.  Improving dose delivery accuracy with EPID in vivo dosimetry: results from a multicenter study , 2021, Strahlentherapie und Onkologie.

[5]  D. Verellen,et al.  Evaluation of automated pre-treatment and transit in-vivo dosimetry in radiotherapy using empirically determined parameters , 2020, Physics and imaging in radiation oncology.

[6]  M. Esposito,et al.  Clinical implementation of 3D in vivo dosimetry for abdominal and pelvic stereotactic treatments. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Marco Esposito,et al.  Estimating dose delivery accuracy in stereotactic body radiation therapy: a review of in-vivo measurement methods. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  R. Werner,et al.  Technological quality requirements for stereotactic radiotherapy , 2020, Strahlentherapie und Onkologie.

[9]  Savino Cilla,et al.  Epid‐based in vivo dose verification for lung stereotactic treatments delivered with multiple breath‐hold segmented volumetric modulated arc therapy , 2019, Journal of applied clinical medical physics.

[10]  Duncan B. McLaren,et al.  EPID‐based in vivo dosimetry using Dosimetry Check™: Overview and clinical experience in a 5‐yr study including breast, lung, prostate, and head and neck cancer patients , 2018, Journal of applied clinical medical physics.

[11]  Elena Villaggi,et al.  SBRT planning for spinal metastasis: indications from a large multicentric study , 2018, Strahlentherapie und Onkologie.

[12]  M. Esposito,et al.  Characterization of EPID software for VMAT transit dosimetry , 2018, Australasian Physical & Engineering Sciences in Medicine.

[13]  L. Azario,et al.  A validation study of a dedicated software for an automated in vivo dosimetry control in radiotherapy , 2018, Medical & Biological Engineering & Computing.

[14]  Pietro Mancosu,et al.  Applying Lean-Six-Sigma Methodology in radiotherapy: Lessons learned by the breast daily repositioning case. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Peter M McCowan,et al.  In vivo dosimetry for lung radiotherapy including SBRT. , 2017, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[16]  Matthias Guckenberger,et al.  ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  H. Eich,et al.  Planning benchmark study for SBRT of early stage NSCLC , 2017, Strahlentherapie und Onkologie.

[18]  Eric Van Uytven,et al.  Clinical Implementation of a Model-Based In Vivo Dose Verification System for Stereotactic Body Radiation Therapy-Volumetric Modulated Arc Therapy Treatments Using the Electronic Portal Imaging Device. , 2017, International journal of radiation oncology, biology, physics.

[19]  A. Morgan,et al.  In vivo dosimetry in UK external beam radiotherapy: current and future usage. , 2017, The British journal of radiology.

[20]  Sasa Mutic,et al.  The report of Task Group 100 of the AAPM: Application of risk analysis methods to radiation therapy quality management. , 2016, Medical physics.

[21]  P. François,et al.  EPID based in vivo dosimetry system: clinical experience and results , 2016, Journal of applied clinical medical physics.

[22]  Elisabetta Cagni,et al.  Lung stereotactic ablative body radiotherapy: A large scale multi-institutional planning comparison for interpreting results of multi-institutional studies. , 2016, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[23]  Marcel van Herk,et al.  Overview of 3-year experience with large-scale electronic portal imaging device-based 3-dimensional transit dosimetry. , 2015, Practical radiation oncology.

[24]  J. Albert,et al.  Quality indicators in radiation oncology. , 2013, International journal of radiation oncology, biology, physics.

[25]  M. Schell,et al.  Stereotactic body radiation therapy: the report of AAPM Task Group 101. , 2010, Medical physics.

[26]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[27]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[28]  G G Hanna,et al.  UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

[29]  Elisabetta Cagni,et al.  Multicentre treatment planning inter-comparison in a national context: The liver stereotactic ablative radiotherapy case. , 2016, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.